Search

Your search keyword '"Morisco F"' showing total 298 results

Search Constraints

Start Over You searched for: Author "Morisco F" Remove constraint Author: "Morisco F" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
298 results on '"Morisco F"'

Search Results

1. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

2. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

3. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

4. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

5. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

6. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

7. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort

8. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

9. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

10. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications

11. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

12. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

13. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

14. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

15. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

16. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

17. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort

18. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

19. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

21. Digestive diseases. 2022-2025 edition

22. Years of life that could be saved from prevention of hepatocellular carcinoma

23. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

24. HepaDisk – A new quality of life questionnaire for HCV patients

25. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

26. Platelets and hepatocellular cancer: Bridging the bench to the clinics

27. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

28. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

29. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

30. Pattern of macrovascular invasion in hepatocellular carcinoma

31. The changing scenario of hepatocellular carcinoma in Italy: an update

32. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

33. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

34. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

35. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

36. Monofocal hepatocellular carcinoma: How much does size matter?

37. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

38. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

39. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

40. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

41. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

42. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

44. Apple polyphenol extracts prevent damage to human gastric epithelial cells in vitro and to rat gastric mucosa in vivo

45. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. (Liver Disease)

46. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

47. Metabolic disorders across hepatocellular carcinoma in Italy

48. HepaDisk – A new quality of life questionnaire for HCV patients

49. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

Catalog

Books, media, physical & digital resources